MolNFT v1 · #90265 · protein
Crystal structure of the novel phenazine prenyltransferase epzp (wildtype)
4EE8: “Crystal structure of the novel phenazine prenyltransferase epzp (wildtype)”. X-ray diffraction, 2 ligands (SO4, CL), 2 pockets (best druggability 0.83). MolNFT v1 #90265 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 4EE8
- Type
- protein
- Length
- 300 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Prenyltransferase
- UniProt
- E5KWG9
- Ligands
- SO4, CL
- Pockets
- 2 · best druggability 0.83
Structure
x-ray diffraction · 1 distinct chain · 36% helix, 27% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Prenyltransferase | protein | 300 | 36% helix, 27% strand | E5KWG9 |
Ligands and binding sites
- SO4 · Sulfate ion · ion · 7 copies · chains A
- CL · Chloride ion · ion · chains A
- ACT · Acetate ion · additive · chains A
- EPE · 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid · additive · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
2 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 239 | 0.83 | 0.95 | 42 | SO4 |
| 2 | 143 | 0.54 | 0.82 | 31 | SO4 |
Compared structures
- 4EE8 · Crystal structure of the Novel Phenazine Prenyltransferase EpzP (wildtype) · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt E5KWG9
- Elsewhere: RCSB PDB 4EE8 · PDBe 4EE8 · UniProt E5KWG9
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.